Novartis : Q2 core EPS up 1%
(CercleFinance.com) - Novartis has reported Q2 core EPS of 1.
56 dollar, up 1% at constant exchange rates (+10% excluding the impact of Roche's core earnings), and core operating income of 4.27 billion dollars, up 5% at constant exchante rates.
The Swiss healthcare group's sales rose 5% at constant exchange rates to nearly 12.8 billion dollars, with strong performance from key growth brands including Entresto, Kesimpta, Cosentyx, Kisqali and Zolgensma.
Novartis has confirmed its guidance for 2022, while upgrading its Sandoz division, expecting low-single digit sales growth and core operating income broadly in line with its level in 2021.
Copyright (c) 2022 CercleFinance.com. All rights reserved.